Inhalation Sciences Sweden AB submits Clinical Trial Application (CTA) for authorization to conduct clinical trial of PreciseInhale [® ]
(Stockholm, Sweden, April 6, 2021) Inhalation Sciences Sweden AB has submitted a CTA (Clinical Trial Application) to the Swedish Medical Product Agency (Läkemedelsverket) for authorization to conduct a clinical trial of its aerosol generating system PreciseInhale[®].“This is a very important milestone for us both strategically and scientifically” says CEO Manoush Masarrat, “A successful clinical validation could be transformational for ISAB and open up an untapped clinical market valued in billions of SEK” In the planned clinical trial, the objective will be to demonstrate that